Loma Vista Medical Custom Case Solution & Analysis

Evidence Brief

Financial Metrics

Capital Raised: 15 million dollars total across Series A and Series B rounds.
Product Pricing: Target price point between 800 and 1200 dollars per catheter, representing a significant premium over standard non-compliant balloons.
Market Size: The global PTCA and PTA balloon catheter market exceeds 1 billion dollars annually.
Manufacturing Costs: Initial prototypes and low-volume production runs indicate unit costs exceeding 400 dollars, with a target to reduce this to under 150 dollars through scale.

Operational Facts

Technology: Proprietary composite fiber-based balloon construction allowing for high-pressure inflation without diameter expansion.
Performance Gap: Current market balloons fail at 20 atmospheres; Loma Vista technology maintains integrity beyond 35 atmospheres.
Manufacturing Yield: Current production processes suffer from high variability and scrap rates exceeding 30 percent in early stages.
Regulatory Status: FDA 510k clearance achieved for specific indications; CE Mark obtained for European distribution.
Headcount: Small core team of fewer than 25 employees, primarily engineering and regulatory focused.

Stakeholder Positions

Alex Tilson: Founder and CEO. Motivated by technical excellence and solving clinical failures but recognizes the capital intensity of a full-scale commercial launch.
Venture Capital Investors: Seeking a liquidity event within the next 18 to 24 months to satisfy fund lifecycle requirements.
Medtronic and Boston Scientific: Incumbent players with massive distribution networks; currently viewing Loma Vista as a R and D laboratory rather than a direct competitor.
Interventional Cardiologists: Expressing high interest in the product for calcified lesions where standard balloons fail.

Information Gaps

Exact acquisition offer price from Medtronic or other strategic buyers.
Detailed breakdown of salesforce recruitment and training costs for a standalone launch.
Long-term clinical trial data comparing InStent outcomes against standard of care over a five-year period.

Strategic Analysis

Core Strategic Question

Loma Vista must decide whether to transition from a technology-focused R and D entity into a full-scale commercial medical device company or exit via acquisition to a strategic partner.

Structural Analysis

The interventional cardiology market is defined by high barriers to entry regarding clinical evidence and distribution reach. While Loma Vista holds superior IP, the bargaining power of buyers—specifically hospital purchasing organizations—is high. These buyers prefer bundled contracts with major vendors like Medtronic or Abbott. The threat of substitutes is low for calcified lesions, but the threat of rivalry is high if incumbents develop bypass technologies or fast-follow products. The value chain analysis reveals that Loma Vista is strongest in product development but weakest in downstream logistics and hospital-level sales relationships.

Strategic Options

Strategic Exit via Acquisition: Sell the company to an incumbent like Medtronic.
- Rationale: Immediate liquidity for investors and the fastest path to patient access.
- Trade-offs: Cedes future upside and control over the technology.
- Resource Requirements: Investment banking fees and legal counsel for due diligence.
Standalone Commercialization: Raise Series C funding to build an internal salesforce and scale manufacturing.
- Rationale: Captures the full value of the premium pricing model.
- Trade-offs: High execution risk and massive capital dilution.
- Resource Requirements: 30 to 50 million dollars in additional capital.
Technology Licensing: License the fiber technology to multiple catheter manufacturers.
- Rationale: Low capital intensity and diversified revenue streams.
- Trade-offs: Difficult to police IP and lower total revenue potential.
- Resource Requirements: Strong legal team to manage complex royalty agreements.

Preliminary Recommendation

Loma Vista should pursue a strategic exit via acquisition. The company has proven the technical superiority of its product, but the cost of building a global sales and distribution network from scratch is prohibitive. The current venture capital climate and the consolidation of hospital purchasing favor a model where specialized technology is folded into a larger portfolio.

Implementation Roadmap

Critical Path

Month 1: Finalize manufacturing validation to prove that high yields are repeatable at scale. This is the primary value driver for an acquirer.
Month 2: Open a formal data room and engage with at least three strategic bidders to create a competitive tension.
Month 3 to 5: Execute intensive due diligence focusing on IP freedom to operate and clinical safety records.
Month 6: Close the transaction and initiate the technology transfer process to the acquirer.

Key Constraints

Manufacturing Stability: If the scrap rate remains high during due diligence, the valuation will drop significantly as the buyer will price in the cost of fixing the process.
IP Litigation: Any pending or threatened patent infringement claims from incumbents will stall a sale indefinitely.
Key Person Risk: The transition depends on Alex Tilson and the lead engineers staying through the integration period.

Risk-Adjusted Implementation Strategy

The primary contingency plan involves a bridge loan if negotiations extend beyond the current cash runway. To mitigate the risk of a single-bidder scenario, the team must maintain active conversations with at least two other medical technology firms in the peripheral vascular space, even if cardiology is the primary focus. This ensures that the company is not forced into a fire sale if the lead bidder withdraws.

Executive Review and BLUF

BLUF

Loma Vista Medical should immediately initiate a sale process to a strategic acquirer. The company has successfully de-risked the technology but faces an insurmountable capital requirement to build the necessary sales infrastructure. Selling now captures the innovation premium before incumbents can develop workarounds or the venture capital runway expires. The focus must be on proving manufacturing scalability to maximize the exit valuation.

Dangerous Assumption

The most consequential unchallenged premise is that the high manufacturing scrap rate is a temporary engineering hurdle rather than a fundamental limitation of the composite fiber technology. If the process cannot be automated, the unit economics will never support the margins required by a strategic buyer.

Unaddressed Risks

Regulatory Shift: Changes in FDA 510k requirements for high-pressure devices could necessitate new, expensive clinical trials, delaying the exit by years.
Incumbent Inertia: Strategic buyers may choose to wait for Loma Vista to run out of cash rather than paying a premium now, especially if they believe they can replicate the IP.

Unconsidered Alternative

The team has not fully explored a joint venture model where a strategic partner provides the salesforce in exchange for equity, allowing Loma Vista to remain independent while solving the distribution gap. This could preserve upside while mitigating the need for a massive Series C raise.